Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

BioCryst Pharmaceuticals Inc

+ Add to Watchlist

BO1:GR

8.952 EUR 0.448 4.77%

As of 13:03:38 ET on 02/27/2015.

Snapshot for BioCryst Pharmaceuticals Inc (BO1)

Open: 9.349 Day's Range: 8.952 - 9.377 Volume: 333
Previous Close: 9.400 52wk Range: 5.160 - 11.716 1-Yr Rtn: +5.19%

Stock Chart for BO1

No chart data available.
  • BO1:GR 9.000
  • 1D
  • 1M
  • 1Y
9.400
Interactive BO1 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BO1

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.8340
Est. PEG Ratio -
Market Cap (M EUR) 643.33
Shares Outstanding (M) 71.86
30 Day Average Volume 535
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BO1

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BO1

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases & cancer. The Company has late-stage compounds in development & continues to discover additional compounds & to progress them to meet the unmet medical needs of patients and physicians.

Jon P StonehousePresident/CEOThomas R Staab II "Tom"Senior VP/CFO/Acctg Ofcr
Lynne PowellSenior VP/Chief Commercial OfcrWilliam P SheridanSenior VP/Chief Medical Ofcr
More Company Profile & Key Executives for BO1

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil